Algert Global LLC Ultragenyx Pharmaceutical Inc. Transaction History

Algert Global LLC

$4.25 Billion
Q4 2024

A detailed history of Algert Global LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Algert Global LLC holds 82,793 shares of RARE stock, worth $3.17 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

82,793

Previous 73,902 12.03%

Holding current value

$3.17 Million

Previous $4.11 Million 15.15%

% of portfolio

0.08%

Previous 0.11%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$42.07 - $57.72 $374,044 - $513,188	8,891 Added 12.03%	82,793 $3.48 Million
Q3 2024 Nov 12, 2024	BUY	$40.21 - $59.36 $948,151 - $1.4 Million	23,580 Added 46.86%	73,902 $4.11 Million
Q2 2024 Aug 14, 2024	BUY	$37.42 - $51.61 $963,639 - $1.33 Million	25,752 Added 104.81%	50,322 $2.07 Million
Q4 2023 Feb 14, 2024	BUY	$31.73 - $49.19 $77,103 - $119,531	2,430 Added 10.98%	24,570 $1.18 Million
Q3 2023 Nov 13, 2023	SELL	$34.92 - $46.66 $164,473 - $219,768	-4,710 Reduced 17.54%	22,140 $789,000
Q2 2023 Aug 14, 2023	SELL	$37.35 - $52.15 $444,838 - $621,106	-11,910 Reduced 30.73%	26,850 $1.24 Million
Q1 2023 May 12, 2023	BUY	$36.99 - $48.71 $1.43 Million - $1.89 Million	38,760 New	38,760 $1.55 Million
Q2 2022 Aug 15, 2022	SELL	$45.8 - $85.4 $140,193 - $261,409	-3,061 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$62.2 - $84.4 $86,582 - $117,484	-1,392 Reduced 31.26%	3,061 $222,000
Q4 2021 Feb 14, 2022	SELL	$73.71 - $87.86 $132,678 - $158,148	-1,800 Reduced 28.79%	4,453 $374,000
Q3 2021 Nov 15, 2021	BUY	$77.92 - $102.4 $487,233 - $640,307	6,253 New	6,253 $564,000

Others Institutions Holding RARE

# of Institutions

345

Shares Held

86.7M

Call Options Held

675K

Put Options Held

846K

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $2.68B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.

Account

Algert Global LLC Ultragenyx Pharmaceutical Inc. Transaction History